Get the Stockscreener App
1.07
1.90%
0.02
After Hours:
1.05
-0.02
-1.87%
Adial Pharmaceuticals Inc stock is traded at $1.07, with a volume of 124.51K.
It is up +1.90% in the last 24 hours and up +4.90% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
See More
Previous Close:
$1.05
Open:
$1.04
24h Volume:
124.51K
Relative Volume:
0.74
Market Cap:
$6.85M
Revenue:
-
Net Income/Loss:
$-6.07M
P/E Ratio:
-0.1419
EPS:
-7.54
Net Cash Flow:
$-7.34M
1W Performance:
-1.83%
1M Performance:
+4.90%
6M Performance:
-2.73%
1Y Performance:
-38.15%
1-Day Range:
$1.00
$1.07
1-Week Range:
$1.00
$1.16
52-Week Range:
$0.765
$4.1699
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
1.07 | 6.85M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
Adial Pharmaceuticals’ New Purchase Agreement with Alumni Capital - TipRanks
Adial Pharmaceuticals (NASDAQ:ADIL) Stock Quotes, Forecast and News Summary - Benzinga
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 71.7% - Defense World
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals revises CEO's compensation package By Investing.com - Investing.com South Africa
Adial Pharmaceuticals revises CEO's compensation package - Investing.com India
Adial Pharmaceuticals secures new patent for AUD therapy By Investing.com - Investing.com South Africa
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations - AOL
Adial Pharmaceuticals, Inc. Updates on Onward Phase 3 Pivotal Trial - Marketscreener.com
Adial Pharmaceuticals secures new patent for AUD therapy - Investing.com
Adial Pharmaceuticals Granted Key U.S. Patent for the - GlobeNewswire
Adial Pharmaceuticals Secures Key Patent for Alcohol Use Disorder Treatment Technology - StockTitan
Alcohol Use Disorder Treatment Market Report Analysis - openPR
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Growth in Short Interest - Defense World
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know - MSN
Equities Analysts Offer Predictions for ADIL FY2024 Earnings - Defense World
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adial Pharmaceuticals (NASDAQ:ADIL) Coverage Initiated at Rodman & Renshaw - Defense World
RODMAN&RENSHAW Upgrades Adial Pharmaceuticals (NASDAQ:ADIL) to “Strong-Buy” - Defense World
ARMISTICE CAPITAL, LLC Acquires New Stake in Adial Pharmaceutica - GuruFocus.com
Rodman & Renshaw sets stock target, buy rating on Adial Pharma, cites potential - Investing.com India
U.S. STOCKS Oklo, Adial Pharma, Sonos - XM
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder - AOL
Adial Pharmaceuticals completes key study for FDA meeting - Investing.com
Adial Pharmaceuticals Announces Positive Topline Results - GlobeNewswire
Adial Pharma's AD04 Drug Hits Key Milestones in Alcohol Use Disorder Treatment Study | ADIL Stock News - StockTitan
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Adial Pharma Reports Mixed Q3: AUD Drug Study Advances Despite Widening Losses | ADIL Stock News - StockTitan
Adial Pharmaceuticals Approves Strategic Changes at Annual Meeting - TipRanks
Adial Pharmaceuticals Appoints Vinay Shah as CFO - Defense World
Adial Pharmaceuticals names new CFO amid strategic growth By Investing.com - Investing.com Australia
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - GlobeNewswire
Adial Pharmaceuticals names new CFO amid strategic growth - Investing.com
Adial Pharma Taps Veteran CFO with $150M+ Fundraising Track Record | Key Executive Move | ADIL Stock News - StockTitan
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference - The Manila Times
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate - AOL
Adial Pharmaceuticals patent expands for alcohol disorder drug - Investing.com
Adial Pharmaceuticals patent expands for alcohol disorder drug By Investing.com - Investing.com Canada
Adial Pharmaceuticals Receives Notice of Allowance for U.S. - GlobeNewswire
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery - GlobeNewswire
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 46.2% in September - Defense World
Analyzing ADI’s price-to-book ratio for the last quarter - US Post News
Adial Pharmaceuticals completes key study stage for AUD drug - Investing.com
Adial Pharmaceuticals Announces Database Lock in - GlobeNewswire
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - StockTitan
Analog Devices Inc. (ADI) Stock: A Year of Declines and Increases - The InvestChronicle
MQS Management LLC Increases Stock Position in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Addex Therapeutics Reports Profitable H1 2024 - TipRanks
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):